CompletedNCT00682448
Metformin or placebo to reduce olanzapine-related metabolic effects
About this title
Read the official source — NCT00682448Medication studyAges 18+United StatesBipolarity
Understand this study
Who was this study for?
Listed age limits: from 18 years.
- Listed locations
- ChicagoSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateAugust 2007
- Recruitment status
- Completed
- Enrollment listed in the registry
- 25
- Sponsor
- Rush University Medical Center
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- Over 18 Years
- Official registry ID
- NCT00682448
- Official title
Show the full official title
Metformin to Prevent the Metabolic Complications of Olanzapine
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Chicago
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Rush University Medical Center, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including Metformin and Placebo.
Who was this study for?
Listed age limits: from 18 years.
